Holec Ashley D, Mandal Subhra, Prathipati Pavan Kumar, Destache Christopher J
Creighton University Medical Microbiology and Immunology, Omaha, NE, United States.
Creighton University School of Pharmacy & Health Professions, Omaha, NE, United States.
Curr HIV Res. 2017;15(6):411-421. doi: 10.2174/1570162X15666171120110145.
Human immunodeficiency virus type-1 (HIV-1) infection leads to acquired immunodeficiency syndrome (AIDS), a severe viral infection that has claimed approximately 658,507 lives in the US between the years 2010-2014. Antiretroviral (ARV) therapy has proven to inhibit HIV-1, but unlike other viral illness, not cure the infection.
Among various Food and Drug Administration (FDA)-approved ARVs, nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs) are most effective in limiting HIV-1 infection. This review focuses on NRTIs mechanism of action and metabolism.
A search of PubMed (1982-2016) was performed to capture relevant articles regarding NRTI pharmacology.
The current classical NRTIs pharmacology for HIV-1 prevention and treatment are presented. Finally, various novel strategies are proposed to improve the efficacy of NRTIs, which will increase therapeutic efficiency of present-day HIV-1 prevention/treatment regimen.
Use of NRTIs will continue to be critical for successful treatment and prevention of HIV-1.
人类免疫缺陷病毒1型（HIV-1）感染会导致获得性免疫缺陷综合征（AIDS），这是一种严重的病毒感染，在2010年至2014年间，美国约有658,507人死于该疾病。抗逆转录病毒（ARV）疗法已被证明可抑制HIV-1，但与其他病毒疾病不同的是，它无法治愈感染。
在食品药品监督管理局（FDA）批准的各种抗逆转录病毒药物中，核苷/核苷酸逆转录酶抑制剂（NRTIs）在限制HIV-1感染方面最为有效。本综述重点关注NRTIs的作用机制和代谢。
检索了PubMed（1982 - 2016年），以获取有关NRTI药理学的相关文章。
介绍了目前用于HIV-1预防和治疗的经典NRTIs药理学。最后，提出了各种新策略以提高NRTIs的疗效，这将提高当今HIV-1预防/治疗方案的治疗效率。
NRTIs的使用对于成功治疗和预防HIV-1仍然至关重要。
